Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Increased to Strong-Buy at Wolfe Research

Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by stock analysts at Wolfe Research to a “strong-buy” rating in a report released on Thursday,Zacks.com reports.

Several other analysts also recently commented on REGN. Royal Bank of Canada dropped their price objective on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Oppenheimer lowered their price target on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. Leerink Partnrs lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. StockNews.com downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. Finally, Citigroup assumed coverage on Regeneron Pharmaceuticals in a research report on Thursday. They set a “neutral” rating and a $895.00 price target for the company. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $1,099.55.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN traded down $25.70 during trading on Thursday, hitting $756.81. The stock had a trading volume of 1,374,549 shares, compared to its average volume of 530,457. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a 12-month low of $753.69 and a 12-month high of $1,211.20. The stock has a market capitalization of $83.17 billion, a price-to-earnings ratio of 18.73, a price-to-earnings-growth ratio of 3.04 and a beta of 0.15. The stock has a 50-day simple moving average of $985.21 and a two-hundred day simple moving average of $1,032.97.

Insider Transactions at Regeneron Pharmaceuticals

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The trade was a 27.07 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 7.48% of the company’s stock.

Institutional Trading of Regeneron Pharmaceuticals

Several hedge funds have recently made changes to their positions in the company. Rakuten Securities Inc. raised its holdings in Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 19 shares during the period. Stephens Consulting LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter valued at about $26,000. Sachetta LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 71.4% in the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 10 shares during the last quarter. FSA Wealth Management LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter worth approximately $26,000. Finally, Crewe Advisors LLC purchased a new stake in Regeneron Pharmaceuticals in the first quarter valued at approximately $28,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.